NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 599)
Posted On: 06/01/2018 8:08:39 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Boosts Drug Development Process through Acquisition of PreEMT Platform
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently acquired the PreEMT™ platform to develop a unique manufacturing method and improve the quality of a key protein-based drug being developed. A recent article discussing the company reads: “The acquisition of the PreEMT technology gives PBIO a footprint in the very large and growing biologics contract research services sector. The company is also busily developing its recently patented Ultra Shear Technology (UST) platform. The scalable, pressure-based UST technology creates stable nanoemulsions of otherwise immiscible fluids. It can be used to extend the shelf life of homogenized dairy products without refrigeration, for example. All the while, PBIO continues its focus on its core product line that generated $2.2 million in 2017 revenue: the development of pressure cycling technology (PCT)-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently acquired the PreEMT™ platform to develop a unique manufacturing method and improve the quality of a key protein-based drug being developed. A recent article discussing the company reads: “The acquisition of the PreEMT technology gives PBIO a footprint in the very large and growing biologics contract research services sector. The company is also busily developing its recently patented Ultra Shear Technology (UST) platform. The scalable, pressure-based UST technology creates stable nanoemulsions of otherwise immiscible fluids. It can be used to extend the shelf life of homogenized dairy products without refrigeration, for example. All the while, PBIO continues its focus on its core product line that generated $2.2 million in 2017 revenue: the development of pressure cycling technology (PCT)-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼